Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Dihydroergotamine Mesylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 196,288Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Enforcement Report - Week of December 25, 2024
    Enforcement Report - Week of December 25, 2024

    25 Dec 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-december-25-2024-24704.pdf

    FDA
    25 Dec 2024
    Share Share
    Satsuma & SNBL Receive FDA Acceptance of STS101 NDA for Migraine
    Satsuma & SNBL Receive FDA Acceptance of STS101 NDA for Migraine

    26 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/satsuma-pharmaceuticals-and-snbl-receive-fda-acceptance-of-nda-resubmission-of-sts101-for-the-acute-treatment-of-migraine-with-or-without-aura-302316089.html

    PR NEWSWIRE
    26 Nov 2024
    Share Share
    Satsuma Resubmits NDA for STS101 (Migraine Treatment)
    Satsuma Resubmits NDA for STS101 (Migraine Treatment)

    30 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/satsuma-pharmaceuticals-and-snbl-resubmits-the-new-drug-application-for-sts101-dihydroergotamine-nasal-powder-for-the-acute-treatment-of-migraine-with-or-without-aura-302292154.html

    PR NEWSWIRE
    30 Oct 2024
    Share Share
    Satsuma And SNBL Announce Publication Of STS101 Study
    Satsuma And SNBL Announce Publication Of STS101 Study

    08 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/satsuma-pharmaceuticals-and-snbl-announce-publication-of-sts101-dihydroergotamine-nasal-powder-pivotal-phase-3-ascend-study-in-cns-drugs-302270104.html

    PR NEWSWIRE
    08 Oct 2024
    Share Share
    Cipla`s Generics Dihydroergotamine Mesylate Receives Approval in US
    Cipla`s Generics Dihydroergotamine Mesylate Receives Approval in US

    20 Sep 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212334

    FDA
    20 Sep 2024
    Share Share
    Gland Pharma's Generic Dihydroergotamine Mesylate Receives Approval in the U.S.
    Gland Pharma's Generic Dihydroergotamine Mesylate Receives Approval in the U.S.

    18 Aug 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215623

    FDA
    18 Aug 2023
    Share Share